Cited by 147Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentPeptidase Inhibition and Analysis

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Manji, Gulam Abbas, Olive, Kenneth P., Saenger, Yvonne M., Oberstein, Paul·2017·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-16-2319

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Targeted therapies and immunotherapy have changed the face of multiple solid malignancies, including metastatic melanoma and lung cancer, but no such therapies exist for pancreatic ductal adenocarcinoma (PDAC) despite the knowledge of key mutations and an increasing understanding of the tumor microenvironment. Until now, most clinical studies have not been biomarker driven in this highly immunosuppressive and heterogeneous cancer. Ongoing basic and translational studies are better classifying the disease in hopes of identifying critical pathways that distinguish the unique PDAC subtypes, which will lead to personalized therapies. In this review, we discuss the current treatment options for metastatic pancreatic cancer and highlight current ongoing clinical trials, which aim to target the stroma and the immune microenvironment either alone or in combination with standard chemotherapy. Identifying biomarkers and key resistance pathways and targeting these pathways in a personalized manner in combination with chemotherapy are likely to yield a more immediate and durable clinical benefit.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2319

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer statistics, 2016
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Of the monotherapy ICBs tested, ipilimumab resulted in one delayed response (of the 27 treated), whereas none of the 14 patients treated with BMS-936559, a programmed death-ligand 1 (PD-L1)–directed IgG4 monoclonal antibody, experienced an objective response (36, 37).”
Result
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848

Show all 77 references

Research works printed but not linked: 1

Khalil, 2016, Modern immunotherapy for the treatment of advance gastrointestinal cancers, Oncology, 30, 85

Sorted by citations

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577
“This represents a significant unmet need, as most chemotherapeutic and immunotherapeutic agents that have proven efficacy in other malignancies have limited efficacy in PDAC (Garrido-Laguna and Hidalgo, 2015; Manji et al., 2017).”
Background
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Orth, M., Metzger, P., Gerum, S., Mayerle, J. V., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 523
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs
Qi, R., Bai, Y., Li, K., Liu, N., Xu, Y., Dal, E., Wang, Y., Lin, R., Wang, H., Liu, Z., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100960 · Cited by 321
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia
McDonald, P. C., Chafe, S. C., Brown, W. S., Saberi, S., Swayampakula, M., Venkateswaran, G., Nemirovsky, O., Gillespie, J. A., Karasinska, J. M., Kalloger, S. E., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.004 · Cited by 224
Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility
Dragomir, M. P., Kopetz, S., Ajani, J. A., & Călin, G. A. (2020) · Gut · doi:10.1136/gutjnl-2019-318279 · Cited by 211
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer
Xiong, G., Liu, C., Yang, G., Feng, M., Xu, J., Zhao, F., You, L., Zhou, L., Zheng, L., Hu, Y., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0777-7 · Cited by 195
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
Adamska, A., Elaskalani, O., Emmanouilidi, A., Kim, M. K., Razak, N. B. A., Metharom, P., & Falasca, M. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.11.007 · Cited by 186
Cancer Cell–Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma
Tian, C., Öhlund, D., Rickelt, S., Lidström, T., Huang, Y., Hao, L., Zhao, R. T., Franklin, O., Bhatia, S. N., Tuveson, D. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2578 · Cited by 179
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 168
Immunotherapy for pancreatic cancer: Barriers and breakthroughs
Torphy, R. J., Zhu, Y., & Schulick, R. D. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12176 · Cited by 154
The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0815-z · Cited by 137
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 128
Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
Nielsen, S. R., Strøbech, J. E., Horton, E. R., Jackstadt, R., Laitala, A., Bravo, M. C., Maltese, G., Jensen, A. R. D., Reuten, R., Rafaeva, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23731-7 · Cited by 122
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
Koltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 119
Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine
Zhou, F., Yang, J., Zhang, Y., Liu, M., Lang, M. L., Li, M., & Chen, W. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1126 · Cited by 98
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Muckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 95
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial
von Einem, J. C., Guenther, C., Volk, H., Grütz, G., Hirsch, D. D., Salat, C., Stoetzer, O. J., Nelson, P. J., Michl, M., Modest, D. P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32230 · Cited by 93
Ultrasonic Cavitation‐Assisted and Acid‐Activated Transcytosis of Liposomes for Universal Active Tumor Penetration
Wang, G., Zhang, C., Jiang, Y., Song, Y. H., Chen, J., Sun, Y., Li, Q., Zhou, Z., Shen, Y., & Huang, P. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202102786 · Cited by 91
m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway
Lin, K., Zhou, E., Shi, T., Zhang, S., Zhang, J., Zheng, Z., Pan, Y., Gao, W., & Yu, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02792-0 · Cited by 91
The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
Liu, X., Xu, J., Zhang, B., Liu, J., Liang, C., Meng, Q., Hua, J., Yu, X., & Shi, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1117-9 · Cited by 87
iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
Lo, J. H.-J., Hao, L., Muzumdar, M. D., Raghavan, S., Kwon, E. J., Pulver, E. M., Hsu, F., Aguirre, A. J., Wolpin, B. M., Fuchs, C. S., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1090 · Cited by 80
Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy
Parveen, A., Subedi, L., Kim, H., Khan, Z., Zahra, Z., Farooqi, M. Q. U., & Kim, S. Y. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030350 · Cited by 81
Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 77
A comprehensive review of pancreatic cancer and its therapeutic challenges
Jiang, S., Fagman, J. B., Ma, Y., Liu, J., Vihav, C., Engström, C., Liu, B., & Chen, C. (2022) · Aging · doi:10.18632/aging.204310 · Cited by 76
A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis
Geng, Y., Fan, J., Chen, L., Zhang, C., Qu, C., Qian, L., Chen, K., Meng, Z., Chen, Z., & Wang, P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0256 · Cited by 70
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Young, K., Hughes, D. J., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816281 · Cited by 66
Cancer-Associated Fibroblasts Confer Gemcitabine Resistance to Pancreatic Cancer Cells through PTEN-Targeting miRNAs in Exosomes
Richards, K. E., Xiao, W., & Hill, R. (2022) · Cancers · doi:10.3390/cancers14112812 · Cited by 69
First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study
Taı̈eb, J., Prager, G. W., Melisi, D., Westphalen, C. B., D’Esquermes, N., Ferreras, A., Carrato, A., & Macarulla, T. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000587 · Cited by 66
Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis
Chan, Y.-T., Tan, H., Lu, Y., Zhang, C., Cheng, C., Wu, J., Wang, N., & Feng, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.020 · Cited by 56
S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways
Fang, D., Zhang, C., Xu, P., Liu, Y., Mo, X., Sun, Q., Abdelatty, A., Hu, C., Xu, H., Zhou, G., et al. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09574-w · Cited by 52
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway
Xu, X., Yang, Y., Mo, X., Wei, J., Zhang, X., & You, Q. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.042 · Cited by 52
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
Lev, A., Lulla, A. R., Wagner, J., Ralff, M. D., Kiehl, J. B., Zhou, Y., Benes, C. H., Prabhu, V. V., Oster, W., Astsaturov, I. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20819 · Cited by 51
CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study
Lin, J.-C., Liu, T.-P., & Yang, P.-M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124019 · Cited by 46
Small molecule inhibitors in pancreatic cancer
Sun, J., Russell, C. C., Scarlett, C. J., & McCluskey, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00447e · Cited by 45
MIF inhibitor, ISO-1, attenuates human pancreatic cancer cell proliferation, migration and invasion in vitro, and suppresses xenograft tumour growth in vivo
Cheng, B., Wang, Q., Song, Y., Liu, Y., Liu, Y., Yang, S., Li, D., Zhang, Y., & Zhu, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-63778-y · Cited by 46
Porcine Models of Pancreatic Cancer
Bailey, K. L., & Carlson, M. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00144 · Cited by 43
Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer
Zhang, W., Qian, W., Gu, J., Gong, M., Zhang, W., Zhang, S., Zhou, C., Jiang, Z., Jiang, J., Han, L., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215976 · Cited by 43
Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked
Evan, G. I., Hah, N., Littlewood, T. D., Sodir, N. M., Campos, T., Downes, M., & Evans, R. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3275 · Cited by 42
Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
Borazanci, E. H., Dang, C. V., Robey, R. W., Bates, S. E., Chabot, J. A., & Hoff, D. D. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2070 · Cited by 42
Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management
Jentzsch, V., Davis, J., & Djamgoz, M. B. A. (2020) · Cancers · doi:10.3390/cancers12113096 · Cited by 45
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
Montemagno, C., Cassim, S., Pouysségur, J., Broisat, A., & Pagès, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114067 · Cited by 39
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer
Shouksmith, A. E., Shah, F., Grimard, M., Gawel, J. M., Raouf, Y. S., Geletu, M., Berger‐Becvar, A., de Araujo, E. D., Luchman, H. A., Heaton, W. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01957 · Cited by 40
Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival
Zhao, J., Soto, L. M. S., Wang, H., Katz, M. H. G., Prakash, L. R., Kim, M. P., Tzeng, C.-W. D., Lee, J. E., Wolff, R. A., Huang, Y., et al. (2021) · Pancreatology · doi:10.1016/j.pan.2021.03.018 · Cited by 38
Silica/gold nanoplatform combined with a thermosensitive gel for imaging-guided interventional therapy in PDX of pancreatic cancer
Xing, L., Li, X., Xing, Z., Li, F., Shen, M., Wang, H., Shi, X., & Du, L. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.122949 · Cited by 37
Paeonol Inhibits Pancreatic Cancer Cell Migration and Invasion Through the Inhibition of TGF-β1/Smad Signaling and Epithelial-Mesenchymal-Transition
Cheng, C., Chen, J., Tang, J., Geng, Y., Zheng, L., Lv, L., Chen, L., & Chen, Z. (2020) · Cancer Management and Research · doi:10.2147/cmar.s224416 · Cited by 37
Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines
Luongo, M., Marinelli, O., Zeppa, L., Aguzzi, C., Morelli, M. B., Amantini, C., Frassineti, A., di Costanzo, M., Fanelli, A., Santoni, G., et al. (2020) · Cancers · doi:10.3390/cancers12102774 · Cited by 42
Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
Rai, V., & Agrawal, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228502 · Cited by 36
LINC01006 promotes cell proliferation and metastasis in pancreatic cancer via miR-2682-5p/HOXB8 axis
Zhang, L., Wang, Y., Zhang, L., You, G., Li, C., Meng, B., Zhou, M., & Zhang, M. (2019) · Cancer Cell International · doi:10.1186/s12935-019-1036-2 · Cited by 35
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33
Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview
Panchal, K., Sahoo, R. K., Gupta, U. D., & Chaurasiya, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107508 · Cited by 33
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Yao, H.-J., Song, W., Cao, R., Ye, C., Zhang, L., Chen, H., Wang, J., Shi, Y., Li, R. P., Li, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33037-x · Cited by 34
CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer
Liu, Y., Wu, T. H., Lu, D., Zhen, J., & Zhang, L. (2018) · The International Journal of Biological Markers · doi:10.1177/1724600817746951 · Cited by 32
Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance
Chen, H., Zhu, X., Sun, R., Ma, P., Zhang, E., Wang, Z., Fan, Y., Zhou, G.-X., & Mao, R. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00951-0 · Cited by 32
Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells
Gioeli, D. G., Snow, C. J., Simmers, M. B., Hoang, S. A., Figler, R. A., Allende, J. A., Roller, D. G., Parsons, J. T., Wulfkuhle, J. D., Petricoin, E. F., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc00755a · Cited by 32
Active ingredients of Inula helenium L. exhibits similar anti-cancer effects as isoalantolactone in pancreatic cancer cells
Yan, Y., Zhang, Q., Zhang, B. L., Yang, B., & Lin, N. (2019) · Natural Product Research · doi:10.1080/14786419.2018.1543676 · Cited by 29
The Membrane Protein Sortilin Can Be Targeted to Inhibit Pancreatic Cancer Cell Invasion
Gao, F., Griffin, N., Faulkner, S., Li, X., King, S. J., Jobling, P., Denham, J. W., Jiang, C. C., & Hondermarck, H. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.05.018 · Cited by 29
Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yam, A. O. W., Bailey, J., Lin, F., Jakovija, A., Youlten, S. E., Counoupas, C., Gunzer, M., Bald, T., Woodruff, T. M., Triccas, J. A., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-21-4025 · Cited by 32
Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma
Hsieh, Y., Liu, T., Chou, C.-J., Chen, H., Lee, K., & Yang, P. (2019) · Genes · doi:10.3390/genes10100766 · Cited by 29
Designer hydrogels: Shedding light on the physical chemistry of the pancreatic cancer microenvironment
Lin, C., & Korc, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.008 · Cited by 29
Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000–2013
Tramontano, A. C., Chen, Y., Watson, T. R., Eckel, A. L., Sheehan, D. F., Peters, M. L. B., Pandharipande, P. V., Hur, C., & Kong, C. Y. (2019) · Medicine · doi:10.1097/md.0000000000018082 · Cited by 27
CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer
Zhu, H., Fang, X., Tuhin, I. J., Tan, J., Ye, J., Jia, Y., Xu, N., Kang, L., Li, M., Lou, X., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04017-x · Cited by 27
Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches
Ashrafizadeh, M., Luo, K., Zhang, W., Aref, A. R., & Zhang, X. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117443 · Cited by 29
Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer
Lu, T., & Prakash, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s279192 · Cited by 27
Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature
Liu, L.-W., Hsieh, Y., & Yang, P. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030130 · Cited by 25
Role of human nucleoside transporters in pancreatic cancer and chemoresistance
Carter, C. J., Mekkawy, A. H., & Morris, D. L. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i40.6844 · Cited by 25
Deep‐Penetrating Triple‐Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models
Tang, X., Du, X., Yu, Y., Qin, M., Qian, L., Zhang, M., Yang, Y., Yu, Q., & Gan, Z. (2022) · Small · doi:10.1002/smll.202202834 · Cited by 25
The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
Čierniková, S., Novisedláková, M., Cholujová, D., Števurková, V., & Mego, M. (2020) · Biomedicines · doi:10.3390/biomedicines8120565 · Cited by 24
Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53
Calheiros, J., Corbo, V., & Saraiva, L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188914 · Cited by 26
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine
Wang, K., Huynh, N. T., Wang, X., Baldwin, G. S., Nikfarjam, M., & He, H. Z. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4193 · Cited by 23
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment
Vitorakis, N., Gargalionis, A. N., Papavassiliou, K. A., Adamopoulos, C., & Papavassiliou, A. G. (2024) · Cancers · doi:10.3390/cancers16162876 · Cited by 25
Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models
Weidle, U. H., Birzele, F., & Nopora, A. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20149 · Cited by 21
New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas
Yao, H.-J., Luo, L., Li, R. Q., Zhao, Y., Zhang, L., Pešić, M., Cai, L., & Li, L. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189220 · Cited by 19
Discovery of a potent and highly selective inhibitor of SIRT6 against pancreatic cancer metastasis in vivo
Xu, X., Zhang, Q., Wang, X., Jin, J., Wu, C., Li, F., Yang, X., Zhao, M., Chen, Y., Lu, S., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.014 · Cited by 19
Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma
Sukeda, A., Nakamura, Y., Nishida, Y., Kojima, M., Gotohda, N., Akimoto, T., & Ochiai, A. (2019) · Pancreas · doi:10.1097/mpa.0000000000001369 · Cited by 19
Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas
Bokas, A., Papakotoulas, P., Sarantis, P., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Cancers · doi:10.3390/cancers12020432 · Cited by 18
Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
Mendes, I., & Vale, N. (2024) · Biomedicines · doi:10.3390/biomedicines12010227 · Cited by 20
The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
Zhang, F., Wang, Y., Yang, F., Zhang, Y., Jiang, M., & Zhang, X. (2022) · Cancer Management and Research · doi:10.2147/cmar.s349442 · Cited by 16
Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno, C., Cassim, S., Leiris, N. D., Durivault, J., Faraggi, M., & Pagès, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126413 · Cited by 17
Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer
Shah, V. M., Dorrell, C., Fatease, A. M. A., Allen-Petersen, B. L., Woo, Y., Bortnyak, Y., Gheewala, R., Sheppard, B. C., Sears, R. C., & Alani, A. W. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040713 · Cited by 18
Jumonji-C domain-containing protein 5 suppresses proliferation and aerobic glycolysis in pancreatic cancer cells in a c-Myc-dependent manner
Wang, H., Wang, J., Liu, J., Wang, Y., Xia, G., & Huang, X. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110282 · Cited by 16
Blocking CTGF-Mediated Tumor–Stroma Interplay in Pancreatic Cancer
Shen, Y., Zhou, Y., Luan, X., & Zhang, W. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.08.005 · Cited by 16
KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism
Muyinda, I. J., Park, J. G., Jang, E., & Yoo, B. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105070 · Cited by 16
Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes
Alzhrani, R. M., Alsaab, H. O., Vanamala, K., Bhise, K., Tatiparti, K., Barari, A., Sau, S., & Iyer, A. K. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000262 · Cited by 16
Poly (l-glutamic acid)-g-methoxy poly (ethylene glycol)-gemcitabine conjugate improves the anticancer efficacy of gemcitabine
Yang, C., Song, W., Zhang, D., Yu, H., Yin, L., Shen, N., Deng, M., Tang, Z., Gu, J., & Chen, X. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.08.037 · Cited by 15
Tumor Microenvironment Role in Pancreatic Cancer Stem Cells
Galindo-Vega, A., Maldonado, V., Mitre-Aguilar, I. B., & Meléndez-Zajgla, J. (2023) · Cells · doi:10.3390/cells12121560 · Cited by 14
Long Non-Coding RNA MIR31HG Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma Cells
Ko, C., Hsieh, Y., & Yang, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126559 · Cited by 14
A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer
Calheiros, J., Silva, R., Barbosa, F., Morais, J., Moura, S. R., Almeida, S., Fiorini, E., Mulhovo, S., Aguiar, T. Q., Wang, T., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03389-5 · Cited by 13
The m6A reader IGF2BP2 promotes pancreatic cancer progression through the m6A-SLC1A5-mTORC1 axis
Pu, X., Wu, Y., Long, W., Sun, X., Yuan, X., Wang, D., Wang, X., & Xu, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03736-8 · Cited by 11
PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1
Zhang, Z., Yang, A., Chaurasiya, S., Park, A. K., Kim, S., Lü, J., Olafsen, T., Warner, S. G., Fong, Y., & Woo, Y. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.022 · Cited by 11
Use of Precision Imaging in the Evaluation of Pancreas Cancer
Korn, R. L., Rahmanuddin, S., & Borazanci, E. H. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_8 · Cited by 11
The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review
Sarfraz, Z., Sarfraz, A., Farooq, M. D., Khalid, M., Cheema, K., Javad, F., Khan, T., Pervaiz, Z., Sarfraz, M., Jaan, A., et al. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01078-8 · Cited by 10
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
You, M. S., Ryu, J. K., Choi, Y. H., Choi, J. H., Huh, G., Paik, W. H., Lee, S. H., & Kim, Y. (2018) · Gut and Liver · doi:10.5009/gnl18220 · Cited by 10
Integrated proteomic profiling identifies amino acids selectively cytotoxic to pancreatic cancer cells
Akinlalu, A., Flaten, Z., Rasuleva, K., Mia, M. S., Bauer, A., Elamurugan, S., Ejjigu, N., Maity, S., Arshad, A., Wu, M., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100626 · Cited by 9
Hypoxia-induced MIR31HG expression promotes partial EMT and basal-like phenotype in pancreatic ductal adenocarcinoma based on data mining and experimental analyses
Ko, C., & Yang, P. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06292-x · Cited by 9
Osteopontin secreted from obese adipocytes enhances angiogenesis and promotes progression of pancreatic ductal adenocarcinoma in obesity
Fukusada, S., Shimura, T., Natsume, M., Nishigaki, R., Okuda, Y., Iwasaki, H., Sugimura, N., Kitagawa, M., Katano, T., Tanaka, M., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00865-y · Cited by 8
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
Tummala, T., Uruchurtu, A. S. S., Cruz, A. D. L., Huntington, K. E., George, A., Liguori, N. R., Zhang, L., Zhou, L., Abbas, A. E., Azzoli, C. G., et al. (2023) · Current Oncology · doi:10.3390/curroncol30110696 · Cited by 8
An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma
Costa, R. B., Benson, A. B., Yaghmai, V., Costa, R. L. B., Zhou, H. S., Behdad, A., Kaplan, J. B., Sadim, M. S., Talamantes, S., & Kalyan, A. (2018) · Case Reports in Oncological Medicine · doi:10.1155/2018/6314392 · Cited by 8
In the Quest for Potent and Selective Malic Enzyme 3 Inhibitors for the Treatment of Pancreatic Ductal Adenocarcinoma
Sheth, G., Shah, S. R., Sengupta, P., Jarag, T., Chimanwala, S., Sairam, K. V. V. M., Jain, V., Talwar, R., Dhanave, A., Raviya, M., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00369 · Cited by 7

Authors: Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P.
Affiliations: NewYork–Presbyterian Hospital (US)
Columbia University Irving Medical Center (US)
Corresponding author: Manji, Gulam Abbas
ORCID: Manji, Gulam Abbas
Olive, Kenneth P.
Saenger, Yvonne M.
Oberstein, Paul
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2017-04-01
Volume: 23
Issue: 7
Pages: 1670-1678
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-16-2319
OpenAlex: W2605366445
Cited by: 145
References: 77
Citations by year: 2026: 5 · 2025: 6 · 2024: 9 · 2023: 19 · 2022: 19 · 2021: 12 · 2020: 26 · 2019: 23 · 2018: 12 · 2017: 13
FWCI: 2.13
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords: metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, targeted therapy, immunotherapy, tumor microenvironment, biomarkers, drug resistance, personalized treatment, combination chemotherapy, clinical trials
MeSH terms: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasm Metastasis, Neoplasms, Second Primary, Carcinoma, Pancreatic Ductal, Precision Medicine, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks